Valuation: Camurus AB

Market Cap 36.18B 3.61B 3.2B 2.99B 2.73B 5.14B 347B 5.19B 14.02B 177B 13.54B 13.24B 569B P/E 2026 *
37.1x
P/E 2027 * 26.4x
Enterprise Value 31.66B 3.16B 2.8B 2.62B 2.38B 4.5B 303B 4.54B 12.27B 155B 11.85B 11.59B 498B EV / Sales 2026 *
11.1x
EV / Sales 2027 * 8.1x
Free-Float
66.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.89%
3 months+1.21%
6 months+12.27%
Current year-8.01%
Current year 54
Extreme 54
71
1 year 54
Extreme 54
71
3 years 46.15
Extreme 46.15
71.07
5 years 21.81
Extreme 21.81
71.07
10 years 7.48
Extreme 7.48
71.07
Manager TitleAgeSince
Chief Executive Officer 63 31/12/2002
Director of Finance/CFO 57 30/06/2025
Chief Tech/Sci/R&D Officer 58 31/12/2024
Director TitleAgeSince
Director/Board Member 63 31/12/2001
Chairman 77 31/12/2014
Director/Board Member 61 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.89%-.--% - - 3.61B
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -1.07%-3.39%+26.07%+58.90% 410.8B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 2.86B 285M 253M 236M 215M 406M 27.36B 410M 1.11B 13.99B 1.07B 1.05B 44.89B 3.75B 373M 332M 310M 282M 532M 35.9B 537M 1.45B 18.35B 1.4B 1.37B 58.9B
Net income 978M 97.43M 86.56M 80.79M 73.64M 139M 9.37B 140M 379M 4.79B 366M 358M 15.37B 1.37B 137M 121M 113M 103M 195M 13.14B 197M 532M 6.72B 513M 502M 21.56B
Net Debt -4.52B -450M -400M -373M -340M -642M -43.27B -648M -1.75B -22.12B -1.69B -1.65B -70.99B -5.81B -579M -514M -480M -437M -825M -55.63B -833M -2.25B -28.44B -2.17B -2.13B -91.27B
Logo Camurus AB
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Employees
316
Date Price Change Volume
30/09/26 US$0.000000 - 16
28/09/26 US$0.000000 - 30
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
608.00SEK
Average target price
793.00SEK
Spread / Average Target
+30.43%

Quarterly revenue - Rate of surprise